Revertant mosaicism in skin: Natural gene therapy

Trends in Molecular Medicine

Volumn 17, Issue 3, 2011, Pages 140-148

  Lai Cheong, Joey E ^a   McGrath, John A ^a   Uitto, Jouni ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROLIFERATION; EPIDERMOLYSIS BULLOSA; GENE CONVERSION; GENE MUTATION; GENE THERAPY; HUMAN; MOSAICISM; PHENOTYPE; REVERTANT MOSAICISM; REVIEW; SOMATIC CELL;

ANIMALS; GENE THERAPY; HUMANS; MOSAICISM; SKIN DISEASES;

EID: 79952441928     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.11.003     Document Type: Review

References (56)

1. Yang T.P., et al. Spontaneous reversion of novel Lesch-Nyhan mutation by HPRT gene rearrangement. Somat. Cell Mol. Genet. 1988, 14:293-303.
2. Wada T., Candotti F. Somatic mosaicism in primary immune deficiencies. Curr. Opin. Allergy Clin. Immunol. 2008, 8:510-514.
3. Jonkman M.F., et al. Revertant mosaicism in epidermolysis bullosa caused by mitotic gene conversion. Cell 1997, 88:543-551.
4. Jonkman M.F., Pasmooij A.M. Revertant mosaicism - patchwork in the skin. N. Engl. J. Med. 2009, 360:1680-1682.
5. Stewart D.M., et al. The phenomenon of spontaneous genetic reversions in the Wiskott-Aldrich syndrome: a report of the workshop of the ESID Genetics Working Party at the XIIth Meeting of the European Society for Immunodeficiencies (ESID). Budapest, Hungary October 4-7, 2006. J. Clin. Immunol. 2007, 27:634-639.
6. Kalb R., et al. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am. J. Hum. Genet. 2007, 80:895-910.
7. Davis B.R., Candotti F. Revertant somatic mosaicism in the Wiskott-Aldrich syndrome. Immunol. Res. 2009, 44:127-131.
8. Brunner H.G., et al. Brief report: reverse mutation in myotonic dystrophy. N. Engl. J. Med. 1993, 328:476-480.
9. Pasmooij A.M., et al. Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa. Am. J. Hum. Genet. 2005, 77:727-740.
10. Boztug K., et al. Multiple independent second-site mutations in two siblings with somatic mosaicism for Wiskott-Aldrich syndrome. Clin. Genet. 2008, 74:68-74.
11. Davis B.R., et al. Unprecedented diversity of genotypic revertants in lymphocytes of a patient with Wiskott-Aldrich syndrome. Blood 2008, 111:5064-5067.
12. Du W., et al. A second-site mutation in the initiation codon of WAS (WASP) results in expansion of subsets of lymphocytes in an Wiskott-Aldrich syndrome patient. Hum. Mutat. 2006, 27:370-375.
13. Hirschhorn R. In vivo reversion to normal of inherited mutations in humans. J. Med. Genet. 2003, 40:721-728.
14. Chen J.M., et al. Gene conversion: mechanisms, evolution and human disease. Nat. Rev. Genet. 2007, 8:762-775.
15. Jonkman M.F., et al. Natural repair mechanisms in correcting pathogenic mutations in inherited skin disorders. Clin. Exp. Dermatol. 2003, 28:625-631.
16. Bittar M., Happle R. Revertant mosaicism and retrotransposons: another explanation of " natural gene therapy" Am. J. Med. Genet. A 2005, 137:222.
17. Wada T., et al. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8697-8702.
18. McClintock B. Controlling elements and the gene. Cold Spring Harb. Symp. Quant. Biol. 1956, 21:197-216.
19. Rakyan V.K., et al. Metastable epialleles in mammals. Trends Genet. 2002, 18:348-351.
20. Whitelaw E., Martin D.I. Retrotransposons as epigenetic mediators of phenotypic variation in mammals. Nat. Genet. 2001, 27:361-365.
21. Davis B.R., et al. Somatic mosaicism in the Wiskott-Aldrich syndrome: molecular and functional characterization of genotypic revertants. Clin. Immunol. 2010, 135:72-83.
22. Boztug K., et al. Large granular lymphocyte proliferation and revertant mosaicism: two rare events in a Wiskott-Aldrich syndrome patient. Haematologica 2007, 92:e43-e45.
23. Lutskiy M.I., et al. Mosaicism of NK cells in a patient with Wiskott-Aldrich syndrome. Blood 2005, 106:2815-2817.
24. Trifari S., et al. Revertant T lymphocytes in a patient with Wiskott-Aldrich syndrome: analysis of function and distribution in lymphoid organs. J. Allergy Clin. Immunol. 2010, 125:439-448. e438.
25. Wada T., et al. Second-site mutation in the Wiskott-Aldrich syndrome (WAS) protein gene causes somatic mosaicism in two WAS siblings. J. Clin. Invest. 2003, 111:1389-1397.
26. Wada T., et al. Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family. Blood 2004, 104:1270-1272.
27. Wada T., et al. Oligoclonal expansion of T lymphocytes with multiple second-site mutations leads to Omenn syndrome in a patient with RAG1-deficient severe combined immunodeficiency. Blood 2005, 106:2099-2101.
28. Arredondo-Vega F.X., et al. Adenosine deaminase deficiency with mosaicism for a " second-site suppressor" of a splicing mutation: decline in revertant T lymphocytes during enzyme replacement therapy. Blood 2002, 99:1005-1013.
29. Hirschhorn R., et al. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat. Genet. 1996, 13:290-295.
30. Stephan V., et al. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N. Engl. J. Med. 1996, 335:1563-1567.
31. Nishikomori R., et al. X-linked ectodermal dysplasia and immunodeficiency caused by reversion mosaicism of NEMO reveals a critical role for NEMO in human T-cell development and/or survival. Blood 2004, 103:4565-4572.
32. Rieux-Laucat F., et al. Inherited and somatic CD3zeta mutations in a patient with T-cell deficiency. N. Engl. J. Med. 2006, 354:1913-1921.
33. Tone Y., et al. Somatic revertant mosaicism in a patient with leukocyte adhesion deficiency type 1. Blood 2007, 109:1182-1184.
34. Uzel G., et al. Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1). Blood 2008, 111:209-218.
35. Wada T., et al. Detection of T lymphocytes with a second-site mutation in skin lesions of atypical X-linked severe combined immunodeficiency mimicking Omenn syndrome. Blood 2008, 112:1872-1875.
36. Hamanoue S., et al. Myeloid lineage-selective growth of revertant cells in Fanconi anaemia. Br. J. Haematol. 2006, 132:630-635.
37. Gache Y., et al. Genetic bases of severe junctional epidermolysis bullosa presenting spontaneous amelioration with aging. Hum. Mol. Genet. 2001, 10:2453-2461.
38. McGrath J.A., et al. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations. J. Invest. Dermatol. 1999, 113:314-321.
39. Pasmooij A.M., et al. A very mild form of non-Herlitz junctional epidermolysis bullosa: BP180 rescue by outsplicing of mutated exon 30 coding for the COL15 domain. Exp. Dermatol. 2004, 13:125-128.
40. Ruzzi L., et al. A homozygous nonsense mutation in type XVII collagen gene (COL17A1) uncovers an alternatively spliced mRNA accounting for an unusually mild form of non-Herlitz junctional epidermolysis bullosa. J. Invest. Dermatol. 2001, 116:182-187.
41. Fine J.D., et al. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J. Am. Acad. Dermatol. 2008, 58:931-950.
42. McGrath J.A., et al. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat. Genet. 1995, 11:83-86.
43. Pasmooij A.M., et al. Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3. J. Clin. Invest. 2007, 117:1240-1248.
44. Almaani N., et al. Revertant mosaicism in recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 2010, 130:1937-1940.
45. Pasmooij A.M., et al. Revertant mosaicism due to a second-site mutation in COL7A1 in a patient with recessive dystrophic epidermolysis bullosa. J. Invest. Dermatol. 2010, 130:2407-2411.
46. Smith F.J., et al. Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex. J. Invest. Dermatol. 2004, 122:73-77.
47. Choate K.A., et al. Mitotic recombination in patients with ichthyosis causes reversion of dominant mutations in KRT10. Science 2010, 330:94-97.
48. Brusasco A., et al. A case of congenital reticular ichthyosiform erythroderma - ichthyosis 'en confettis'. Dermatology 1994, 188:40-45.
49. Schuilenga-Hut P.H., et al. Partial revertant mosaicism of keratin 14 in a patient with recessive epidermolysis bullosa simplex. J. Invest. Dermatol. 2002, 118:626-630.
50. Darling T.N., et al. Revertant mosaicism: partial correction of a germ-line mutation in COL17A1 by a frame-restoring mutation. J. Clin. Invest. 1999, 103:1371-1377.
51. Mavilio F., et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 2006, 12:1397-1402.
52. Baum C., et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003, 101:2099-2114.
53. Cavazzana-Calvo M., et al. The future of gene therapy. Nature 2004, 427:779-781.
54. Nienhuis A.W., et al. Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 2006, 13:1031-1049.
55. Gostynski A., et al. Adhesive stripping to remove epidermis in junctional epidermolysis bullosa for revertant cell therapy. Br. J. Dermatol. 2009, 161:444-447.
56. Al Aboud K., et al. Kindler syndrome: two additional features. Dermatol. Online J. 2003, 9:20.